CJC-1131. ConjuChem.
ConjuChem is developing CJC-1131, a drug affinity complex conjugate of glucagon-like peptide 1 for the potential treatment of type 2 diabetes. In August 2003, a phase I/II trial was completed and a phase II trial was expected to begin in October.
Giannoukakis
Nick
N
University of Pittsburgh School of Medicine, Diabetes Institute, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA. ngiann1@pitt.edu
D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D008301:Maleimides / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D010455:Peptides / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D013329:Structure-Activity Relationship
C473712:CJC 1131; D007004:Hypoglycemic Agents; D008301:Maleimides; D010455:Peptides